Evidence map›Paper›PMID 31919760›Full record

ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2020

An overview of yeast probiotics as cancer biotherapeutics: possible clinical application in colorectal cancer.

S Shamekhi, H Lotfi, J Abdolalizadeh, E Bonabi, N Zarghami

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 41 citations in OpenAlex.

  1. Review
  2. Review
  3. Yeast as a Model for Human Disease.International journal of molecular sciences · 2026
    Review
  4. Review
  5. Mycobiome: an underexplored kingdom in cancer.Microbiology and molecular biology reviews : MMBR · 2025
    Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

S ShamekhiNutrition Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
H LotfiDepartment of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
J AbdolalizadehDrug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
E BonabiDepartment of Medical Microbiology, Faculty of Medicine, Istanbul Aydin University, Istanbul, Turkey.
N ZarghamiNutrition Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. zarghami@tbzmed.ac.ir.ORCID http://orcid.org/0000-0002-4236-4537
Tabriz University of Medical Sciences · IRIstanbul Aydın University · TR

Funding

Nutrition Research Center, Tabriz University of Medical Sciences, Tabriz, Iran 5/71/1228
6 · The paper itself

Abstract

The previous reports have established a strong link between diet, lifestyle, and gut microbiota population with the onset of the colorectal cancer (CRC). Administration of probiotics has become a particular interest in prevention and treatment of CRC. As potential dietary complements, probiotics might be able to lower the risk of CRC and manage the safety of traditional cancer therapies such as surgery, radiation therapy, and chemotherapy. This review investigates the promising effects of probiotics as biotherapeutics, with due attention to possible clinical application of yeast probiotics in prevention and treatment of CRC. In addition, various underlying anti-cancer mechanisms are covered here based on scientific evidence and findings from numerous experimental studies. Application of probiotics as biotherapeutics in CRC, however, needs to be approved by human clinical trials. It is of prime concern, to find potential probiotic strains, effective doses for administrations and regimes, and molecular mechanisms involved in prevention and treatment.

Indexed as

YeastsAntineoplastic Agentsbeta-GlucansClinical Trials as TopicColorectal NeoplasmsDatabases, FactualDisease ProgressionFolic AcidGastrointestinal MicrobiomeHumansInflammationMAP Kinase Signaling SystemProbioticsSaccharomyces boulardiiSaccharomyces cerevisiaeSignal TransductionAntineoplastic Agentsbeta-GlucansFolic AcidColorectal cancerMolecular mechanismsProbioticsYeasts

Identifiers

PMID31919760
OpenAlexW3000698309

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.